Ignite Creation Date:
2024-05-06 @ 1:55 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04162340
Status:
UNKNOWN
Last Update Posted:
2021-05-19
First Post:
2019-11-11
Brief Title:
CD4-specific CAR T Cells CD4 CAR T Cells for RelapsedRefractory T Cell Malignancies
Sponsor:
iCell Gene Therapeutics
Organization:
iCell Gene Therapeutics
Study Overview
Official Title:
CD4-specific CAR T Cells CD4 CAR T Cells for RelapsedRefractory T Cell Malignancies
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I interventional single arm open label treatment study to evaluate the safety and tolerability of CD4 CAR T cells in patients with relapsed andor refractory T cell lymphoma
Detailed Description:
CD4-specific CAR is a chimeric antigen receptor immunotherapy treatment designed to treat lymphomaleukemia expressing CD4 antigen CD4 T cell lymphomas are a subset of leukemias and lymphomas that are positive for the surface protein CD4 The purpose of this study is to evaluate the efficacy and safety of CD4 CAR T cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None